Skip to main content

Advertisement

Log in

Erlotinib and Pancreatic Adenocarcinoma: Uncertainty and Hope

  • Pancreatic Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. O’Reilly EM. Refinement of adjuvant therapy for pancreatic cancer. JAMA. 2010;304:1124–5.

    Article  PubMed  Google Scholar 

  2. Bao PQ, Ramanathan RK, Krasinkas A, et al. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol. 2011;18:1122–9.

    Article  PubMed  Google Scholar 

  3. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature. 2010;467(7315):543–9.

    Article  PubMed  Google Scholar 

  4. Roukos DH. Cancer genome explosion and systems biology: Impact on surgical oncology? Ann Surg Oncol. 2011;18(1):12–15.

    Article  PubMed  Google Scholar 

  5. Katsios C, Roukos DH. Individual genomes and personalized medicine: Life diversity and complexity. Per Med. 2010;7(4):347–50.

    Google Scholar 

  6. Roukos DH. Bionetworks-based personalized medicine versus comparative effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn. 2010;10(3):247–50.

    Article  PubMed  Google Scholar 

  7. Roukos DH. Next generation, genome sequencing-based biomarkers: Concerns and challenges for medical practice. Biomark Med. 2010;4(4):583–6.

    Article  PubMed  Google Scholar 

  8. Roukos DH. Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices. 2011;8(2):123–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Charalambos Batsis MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zoras, O., Batsis, C. Erlotinib and Pancreatic Adenocarcinoma: Uncertainty and Hope. Ann Surg Oncol 18 (Suppl 3), 246–247 (2011). https://doi.org/10.1245/s10434-011-1809-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-011-1809-x

Keywords

Navigation